HCPCS Code J9999 Antineoplastic Drugs

Key Takeaways

HCPCS code J9999 is the not otherwise classified (NOC) code for antineoplastic drugs that do not yet have a specific HCPCS J-code assigned by CMS.

J9999 is used when a newly FDA-approved chemotherapy agent lacks its own J-code, requiring providers to report the drug name, dose, strength, and NDC on the claim.

J9999 differs from J3490 by drug category: J9999 is exclusive to antineoplastic drugs, while J3490 covers other unclassified injectable drugs not in the chemotherapy range.

Pabau’s claims management software helps oncology billing teams track J9999 submissions, attach supporting documentation, and manage the transition to drug-specific codes when CMS assigns them.

Every oncology billing team eventually encounters a newly FDA-approved chemotherapy drug with no dedicated J-code on the books. Until CMS catches up, providers rely on HCPCS code J9999 to keep claims moving and payments flowing. Getting this code right the first time matters: missing a single field in your supporting documentation can trigger a denial that takes weeks to resolve through claims management software and manual appeals.

This reference guide covers the definition, billing workflow, NDC reporting rules, payer-specific guidelines, and the transition pathway to a permanent drug-specific J-code when CMS finally assigns one. The guidance reflects CMS standards and MAC-published billing rules in effect for 2026.

HCPCS code J9999: definition and code description

HCPCS code J9999 is the official unlisted, not otherwise classified (NOC) code for antineoplastic drugs under the CMS Healthcare Common Procedure Coding System. Its full description reads: Not otherwise classified, antineoplastic drugs. As a result, it sits at the end of the HCPCS Level II chemotherapy drug range (J9000-J9999), making it the catch-all code for the whole category.

The National Cancer Institute’s SEER*Rx CanMED database classifies J9999 as a non-oral chemotherapy drug (Oral: No), meaning it applies only to antineoplastic agents given by injection or infusion. If a drug is taken orally, a different NOC code applies.

Because J9999 is an NOC code, it carries no fixed payment rate in the CMS Physician Fee Schedule. Payers price these claims individually, typically based on the drug’s Average Sales Price (ASP) or Average Wholesale Price (AWP), plus any administration markups.

When to use HCPCS code J9999

Use J9999 when two conditions are both true: the drug is an antineoplastic agent, and it does not yet have a dedicated HCPCS J-code in the current year’s code set.

In most cases, the trigger is FDA approval of a new oncology drug. CMS typically assigns a permanent J-code through its quarterly HCPCS update cycle, but the lag between FDA approval and code assignment often runs several months. During that window, providers must bill J9999 or risk submitting a claim with no recognizable procedure code at all.

Situations where J9999 applies

• A newly approved immunotherapy or targeted therapy drug has no assigned J-code in the current HCPCS code set.
• Your MAC or state Medicaid agency has issued a billing bulletin explicitly directing providers to use J9999 for a specific drug.
• The drug is administered parenterally (IV infusion, subcutaneous injection) and falls within the antineoplastic therapeutic class.
• You are billing a hospital outpatient or physician office claim and no C-code (e.g., C9399) has been activated for the drug by the hospital’s specific payer.

Situations where J9999 does not apply

• The drug already has a permanent J-code in the current year’s HCPCS. Defaulting to J9999 when a specific code exists is a coding error that invites audits.
• The drug is not an antineoplastic agent. Use J3490 (unclassified drugs, other than oral) or J3590 (unclassified biologics) instead, depending on the drug class.
• The drug is administered orally. Oral chemotherapy agents use different HCPCS coding pathways.

Common drugs billed under J9999

In practice, the roster of drugs billed under J9999 changes each year as CMS assigns permanent codes to previously unclassified agents. The drugs below represent confirmed historical use of J9999, documented through official state Medicaid billing bulletins published by North Carolina Medicaid and other authoritative sources.

• Talquetamab-tgvs (Talvey): A GPRC5D-directed bispecific antibody for relapsed or refractory multiple myeloma. NC Medicaid confirmed J9999 billing effective September 1, 2023.
• Glofitamab-gxbm (Columvi): A CD20xCD3 bispecific antibody for relapsed or refractory diffuse large B-cell lymphoma. NC Medicaid confirmed J9999 billing effective June 27, 2023.
• Retifanlimab-dlwr (Zynyz): A PD-1 inhibitor for Merkel cell carcinoma and other solid tumors. NC Medicaid confirmed J9999 billing via an official billing guidelines bulletin.
• Dostarlimab-gxly (Jemperli): A PD-1 inhibitor for endometrial cancer. NC Medicaid confirmed J9999 billing effective May 17, 2021.
• Melphalan flufenamide (Pepaxto): An alkylating peptide-drug conjugate for multiple myeloma. NC Medicaid confirmed J9999 billing through an official guideline bulletin published June 2021.
• Pembrolizumab (Keytruda) and nivolumab (Opdivo): Both drugs used J9999 before CMS assigned dedicated J-codes. Pembrolizumab now has its own code; nivolumab is represented by J9299.

Always verify whether a drug has moved to a permanent J-code before submitting a claim. CMS publishes quarterly HCPCS updates, and a drug that required J9999 in Q1 may have a specific code by Q3 of the same year. The AAPC Codify HCPCS lookup is a fast way to confirm current code status.

Documentation requirements and NDC reporting

NOC codes like J9999 require more documentation than standard J-codes because payers cannot look up a pre-priced descriptor. As a result, incomplete submissions are the primary reason J9999 claims are returned or denied. Solid medical forms and documentation workflows reduce this risk significantly.

Required documentation for J9999 claims

• Drug name: Full generic name plus brand name (e.g., “talquetamab-tgvs (Talvey)”).
• Dose administered: Exact quantity administered in the encounter, expressed in the unit recognized by the drug’s labeling.
• Drug strength: Strength per vial or unit (e.g., mg/mL).
• Route of administration: IV infusion, subcutaneous injection, or other parenteral route.
• Medical necessity statement: Diagnosis code(s) supporting the clinical indication, consistent with FDA-approved labeling or an accepted off-label use supported by an authoritative compendia.
• National Drug Code (NDC): Required by Medicare and many Medicaid programs (see NDC section below).
• Prescribing physician’s order or treatment authorization.

Maintaining HIPAA-compliant documentation practices is non-negotiable when attaching this supporting evidence to claims. Each document becomes part of the medical record and payers may audit it.

NDC reporting requirements

The National Drug Code (NDC) is an 11-digit identifier the FDA assigns to every drug sold commercially. Medicare Part B and most Medicaid programs require NDC reporting on the claim form (CMS-1500 or electronic 837P equivalent) for J9999 claims.

NDC reporting format follows the qualifier “N4” on the CMS-1500, followed by the 11-digit NDC, the unit of measure qualifier, and the quantity. In fact, errors in NDC format are a leading cause of J9999 claim rejections. Your prescription management workflows should capture the NDC at dispensing, not after the fact at the billing stage.

J9999 vs J3490, J3590, and C9399: choosing the right unlisted code

Four unlisted drug codes cover the territory of drugs without a dedicated HCPCS code. Choosing the wrong one is a common error that triggers claim edits and payer requests for additional information.

The First Coast Service Options (FCSO) Medicare billing contractor confirms that J3490 and J9999 are both unlisted codes for injection services, but their usage is determined by drug category, not provider setting. A cancer center billing for a newly approved immunotherapy uses J9999. A doctor’s office billing for an unclassified pain management injectable uses J3490. For more context on CPT-based billing workflows in clinical specialties, see Pabau’s CPT-based billing workflows guide.

Medicare and Medicaid billing guidelines

Reimbursement policies for J9999 vary by payer type. Medicare Part B, state Medicaid programs, and commercial insurers each apply different pricing and coverage rules to NOC antineoplastic claims.

Medicare Part B

Under Medicare Part B, drugs administered in a physician office or outpatient clinic setting are typically paid at ASP plus a percentage markup (currently ASP + 6% for most Part B drugs). For J9999, there is no pre-loaded ASP in the fee schedule because the code covers multiple drugs. Instead, the MAC prices the claim manually based on the ASP of the specific drug reported in the supporting documentation.

Submit the drug-specific information on a separate attachment or in the claim’s narrative field (Box 19 on CMS-1500). Without this, the MAC cannot price the claim and will return it as incomplete. Check the CMS Physician Fee Schedule lookup to verify whether a drug-specific code has been assigned before defaulting to J9999.

Chemotherapy administration codes (CPT 96413 for the initial infusion hour and CPT 96415 for each additional hour) are billed separately and in addition to J9999 for the drug itself. Include both the drug code and the administration codes on the same claim. Maintaining solid primary care HIPAA compliance documentation standards applies equally to oncology practices billing under Part B.

Medicaid (PADP)

Similarly, most state Medicaid programs cover newly approved antineoplastic drugs under a Physician Administered Drug Program (PADP). Coverage is drug-specific: Medicaid agencies issue billing guideline bulletins when they add a new drug to PADP coverage, specifying J9999 as the billing code until a permanent code is assigned.

NC Medicaid’s published bulletins for talquetamab-tgvs (Talvey), glofitamab-gxbm (Columvi), retifanlimab-dlwr (Zynyz), dostarlimab-gxly (Jemperli), and melphalan flufenamide (Pepaxto) all confirm the same pattern: effective date of coverage is set at the state level, claims must be submitted with J9999, and prior authorization is required.

However, state Medicaid coverage policies vary significantly. A drug covered under NC Medicaid’s PADP may have different billing requirements in California, Texas, or New York. Always verify against your state agency’s current fee schedule and billing bulletins. Robust patient data security tools ensure your practice stores and transmits clinical documentation supporting Medicaid claims in line with HIPAA.

Commercial payers

By contrast, commercial payer policies for J9999 are the least consistent. Most large commercial payers (UnitedHealthcare, Cigna, Aetna, Anthem) have medical policies for specific oncology drugs that will determine whether J9999 is accepted or whether a different code is required. Check each payer’s drug policy portal before submission. The Washington State Health Care Authority’s published list of drugs billed under miscellaneous codes J3490, J3590, J9999, and C9399 is a useful reference model for understanding how authorization-required drugs are grouped across payer types.

Simplify J9999 billing with Pabau

Pabau's claims management tools help oncology and specialty practices track NOC drug claims, attach supporting documentation, and reduce J9999 denial rates. See how it works for your practice.

Book a demo

Prior authorization and claim denial prevention

Most payers require prior authorization for J9999 claims, including Medicare Advantage plans, Medicaid managed care programs, and commercial insurers. Even traditional Medicare fee-for-service may require a coverage decision for specific high-cost antineoplastic agents.

Prior authorization checklist for J9999

• Confirm the payer’s prior auth pathway: Submit authorization requests through the payer’s drug management portal, not the standard procedure PA portal. Many payers route oncology drug authorizations through a specialty pharmacy benefit manager.
• Include the drug’s full clinical rationale: Reference the FDA-approved indication and attach the treating oncologist’s order. For off-label use, include trusted reference guide citations (NCCN, DrugDex, AHA).
• Specify the drug name in the PA request: Do not submit the PA under the J9999 code alone. Always pair it with the drug’s full name, NDC, and planned administration schedule.
• Document the diagnosis codes: Payers routinely deny PA requests without ICD-10-CM diagnosis codes aligned to the drug’s indication. Use the most specific code available.
• Track authorization expiration dates: Most J9999 PAs are time-limited (30-90 days). Confirm expiration before each treatment cycle and renew the authorization in advance.

Common reasons for J9999 claim denials

• Missing or incorrectly formatted NDC on the claim form.
• No supporting documentation attached identifying the specific drug and dose.
• Drug now has a permanent specific J-code but claim was still submitted with J9999.
• The provider did not obtain prior authorization before administration.
• Diagnosis codes do not support medical necessity for the specific drug administered.
• Incorrect unit count reported for the drug’s billing unit.

Oncology practices handling high volumes of J9999 claims benefit from structured practice management software features that flag missing documentation fields before claim submission and track payer-specific requirements by drug. Integrating drug authorization tracking into your billing workflow through digital intake forms ensures the clinical record supports the claim from the first appointment.

Transitioning to a drug-specific J-code

In short, J9999 is always a temporary billing solution. CMS assigns permanent J-codes for high-utilization antineoplastic drugs through its quarterly HCPCS update process. The transition to a permanent code is straightforward but requires active monitoring to avoid continued J9999 use after the new code is active.

How CMS assigns permanent J-codes

1. FDA approval: A new antineoplastic drug receives FDA approval and enters the market. Providers begin billing under J9999.
2. CMS application window: Manufacturers submit a HCPCS Level II code application to CMS. CMS reviews applications quarterly and publishes its decisions in HCPCS update files.
3. Code assignment: CMS assigns a permanent J-code with a specific effective date. The code typically takes effect on January 1 (annual update) or at the start of a calendar quarter (quarterly update).
4. Payer notification: CMS publishes the new code in its quarterly update files. MACs and Medicaid agencies issue billing bulletins confirming the transition date.
5. Provider action: Update your charge master, billing system, and any standing prior authorizations to reflect the new permanent code. Payers will deny or return claims submitted after the effective date using J9999 for a drug that now has a specific code.

Pembrolizumab (Keytruda) and nivolumab (Opdivo) are well-known examples of drugs that transitioned through this pathway. Both were billed under J9999 for a period before receiving permanent codes. Nivolumab now bills under J9299. Maintaining clean EHR integration for billing accuracy helps ensure your charge master reflects the current year’s HCPCS updates automatically rather than requiring manual annual audits.

Use the PGM Billing HCPCS lookup tool or the NLM Clinical Tables HCPCS API for automated lookups to verify code status in real time before claim submission. The AAPC Codify HCPCS range browser also provides effective date data alongside each code’s current status, which is useful for confirming exactly when a permanent code replaces J9999 for a specific drug.

Conclusion

HCPCS code J9999 fills a critical gap in oncology billing, giving providers a valid pathway to bill for newly approved antineoplastic drugs before CMS assigns a permanent code. Overall, the code itself is straightforward; the complexity lies in the documentation, NDC reporting, and payer-specific authorization requirements that accompany every J9999 claim.

Practices that build J9999 into a structured billing workflow, from NDC capture at dispensing through quarterly code audits, see far fewer denials and shorter payment cycles. Pabau’s claims management software gives oncology and specialty practices the tools to track NOC drug submissions, manage supporting documentation, and automate the transition to drug-specific codes as CMS updates roll out. To see how Pabau handles these workflows in practice, book a demo with the team.

Continue your research

Need to track IVF-related procedure billing? IVF CPT codes covers the CPT billing framework for assisted reproductive technology procedures, including documentation and payer requirements.

Looking for best-practice documentation frameworks? Best medical practice management software reviews the platforms that handle billing documentation workflows for specialty practices.

Managing staff who handle oncology billing tasks? Pabau’s team management software lets you assign billing responsibilities, track task completion, and audit documentation quality across your clinical team.

Frequently Asked Questions